New research sheds light on role of KRAS mutations in pancre

Researchers at The University of Texas MD Anderson Cancer Center have uncovered a functional role for KRAS mutations in pancreatic cancer and rapidly translated these findings into a novel therapeutic approach combining a KRAS G12D inhibitor with immune checkpoint inhibitors for early- and late-stage KRAS G12D-mutant pancreatic cancer.

Related Keywords

Texas , United States , Sid Richardson , Kathleen Mcandrews , Raghu Kalluri , Krishnan Mahadevan , Anirban Maitra , Timothy Heffernan , Lily Ramsey , National Cancer Institute , Md Anderson Translational Research To Advance Therapeutics , Khalifa Bin Zayed Al Nahyan Foundation , Lustgarten Foundation , Oncology Research , University Of Texas Md Anderson Cancer Center , Sidw Richardson Foundation , Cancer Center , Developmental Cell , Cancer Cell , Cancer Biology , Translational Molecular Pathology , Translational Research , Advance Therapeutics , Therapeutics Discovery , Break Through Cancer , Khalifa Bin Zayed Al Nahyan , Cancer , Immunotherapy , Pancreatic Cancer , Reclinical , Fell , Ell Death , Clinical Trial , Enetic , Immune System , Ncology , Pathology , Mh , Research , Herapeutics , Fraction , Humor ,